Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Oclacitinib Maleate

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet Zoetis Inc. Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:07 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:06 AM UTC

Sources:
Image coming soon
Oclacitinib Maleate

Oclacitinib Maleate

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Zoetis Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Oclacitinib Maleate

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Species commonly shown: Both, Dog, No Use Class Stated Or Implied.

Generic name
Oclacitinib Maleate
Brand names
apoquel®, apoquel® chewable
Manufacturer
Zoetis Inc.
Species
Both, Dog, No Use Class Stated Or Implied
Dosage forms
Tablet, Chewable Tablets
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
apoquel® apoquel® chewable
Dosage forms
Tablet Chewable Tablets

Indications / Uses

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Warnings / Contraindications

APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

  • APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

Side Effects

Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Seizure NOS.

FAQ

Both, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet, Chewable Tablets

Related Conditions

Atopic Dermatitis (Canine Atopy) Demodicosis Pruritus (itching, undifferentiated)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches
  • The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents
  • Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia
  • wobbly/unsteady walking (1 reports)
  • Diabetes mellitus (1 reports)
  • Dermal thickening (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches
  • The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents
  • Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia
  • wobbly/unsteady walking
  • Diabetes mellitus

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Diabetes mellitus (1 reports)
  • Dermal thickening (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Zoetis Inc.
Form: Chewable Tablets, Tablet
Identifiers:
NADA: 141345 NADA: 141555 NDC Package: 54771-8721-1 NDC Package: 54771-8721-2 NDC Package: 54771-8721-3 NDC Package: 54771-8722-1 NDC Package: 54771-8722-2 NDC Package: 54771-8722-3 NDC Package: 54771-8723-1 NDC Package: 54771-8723-2 NDC Package: 54771-8723-3 NDC Package: 82712-2004-1 NDC Package: 82712-2004-2 NDC Package: 82712-2004-3 NDC Product: 54771 NDC Product: 82712
Source metadata:

Warnings / Contraindications

APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

  • High: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
24
Species represented
2
Grouped by Body System
Digestive (4) · Diarrhea, Decreased appetite, Bloody diarrhoea Skin & allergy (1) · Hair loss Neurologic (2) · Unsteady walking (ataxia), Depression Behavior (2) · Behavioral disorder (unspecified), Aggression Other (23) · Diabetes mellitus, Dermal thickening, Decreased urine concentration
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Neurologic 1 Cat 1
Other 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (21) Cat (11)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Neurologic Cat Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Digestive Dog Serious - 1
Other Cat Non-serious - 1
Behavior Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

2

apoquel® chewable

SPL · SPL

Open original
FDA Structured Product Label

apoquel® chewable

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-555
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet

Dogs

Indication

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Dosage

The dose is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.

apoquel®

SPL · SPL

Open original
FDA Structured Product Label

apoquel®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-345
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet

Dogs

Indication
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Dosage
Administer orally 0.18 to 0.27 mg/per pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.
Limitations
APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

N-141555-Q-0004-OT-AA_foi.pdf

FOI · FOI

Open original

UCM363901.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Tablet • Oral
Applications: NADA 141-555 • NADA 141-345
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 106 • Cat 0 • View
Case summaries: 32 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: L20.9
Atopic dermatitis, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Diabetes mellitus (1) Dermal thickening (1) Depression (1) Decreased red blood cell count (1) Decreased appetite (1) Death by euthanasia (1) Death (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141345 NADA: 141555 NDC Package: 54771-8721-1 NDC Package: 54771-8721-2 NDC Package: 54771-8721-3 NDC Package: 54771-8722-1 NDC Package: 54771-8722-2 NDC Package: 54771-8722-3 NDC Package: 54771-8723-1 NDC Package: 54771-8723-2 NDC Package: 54771-8723-3 NDC Package: 82712-2004-1 NDC Package: 82712-2004-2 NDC Package: 82712-2004-3 NDC Product: 54771 NDC Product: 82712
Package NDC Product NDC Form / Route Status
54771-8721-1 54771 -
54771-8721-2 54771 -
54771-8721-3 54771 -
54771-8722-1 54771 -
54771-8722-2 54771 -
54771-8722-3 54771 -
54771-8723-1 54771 -
54771-8723-2 54771 -
54771-8723-3 54771 -
82712-2004-1 82712 -
82712-2004-2 82712 -
82712-2004-3 82712 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • N-141555-Q-0004-OT-AA_foi.pdf • FOI summary • Official • Oct. 17, 2024
    FDA FOI summary for application 141555
  • UCM363901.pdf • FOI summary • Official • Aug. 17, 2023
    FDA FOI summary for application 141345

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 14 Clinical 6 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclo… (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Clinical, 2026-04-11)
  • usage: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. (Clinical, 2026-04-16)
  • contraindications: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclo… (Official, 2026-04-22)
  • contraindications: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclo… (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Official, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, INEFFECTIVE, ATOPY CONTROL, Diarrhoea, Lethargy (see also Central nervous system depression… (Official, 2026-02-12)
  • usage: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. (Official, 2026-04-22)
  • usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-17)
  • usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-16)
  • usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-15)
  • usage: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. (Official, 2026-04-15)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-17 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-17 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-17 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-17 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-17 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-17 10:08 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-16 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 10:07 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-16 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-16 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-16 10:05 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-15 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-15 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
apoquel® chewable
RX
Oclacitinib
Chewable Tablets • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-555 Approved Oct 17, 2024
apoquel®
RX
Oclacitinib
Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-345 Approved Aug 17, 2023

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet
Dogs
Indication

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Dosage

The dose is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet
Dogs
Indication
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Dosage
Administer orally 0.18 to 0.27 mg/per pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.
Limitations
APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

FDA page: Open in Animal Drugs @ FDA

Usage

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Diarrhea (1) • Dog Decreased appetite (1) • Dog Bloody diarrhoea (1) • Dog Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Hair loss (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog Depression (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat Aggression (1) • Dog

Showing top 5 for Behavior.

Other
Diabetes mellitus (1) • Dog Dermal thickening (1) • Dog Decreased urine concentration (1) • Cat Decreased red blood cell count (1) • Dog Decreased haematocrit (1) • Dog
Show more (18)
Death by euthanasia (1) • Dog Death (1) • Dog Claw / hoof / nail disorder NOS (1) • Dog Cartilage degeneration (1) • Dog Bone and joint disorder NOS (1) • Dog Bloody stool (1) • Dog Blood in urine (1) • Cat Azotaemia (1) • Cat Aspiration pneumonia (1) • Cat Arrhythmia (1) • Cat Anuria (1) • Cat Anaemia NOS (1) • Cat Agitation (1) • Dog Acute renal failure (1) • Cat Active urine sediment (1) • Dog Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal red blood cell (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier (unspecified), Male, 6.9 year, 3.36 kilogram • Drug: MSK, Tablet, Oral • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075257
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 6.90 Year
  • Weight: 3.360 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Ongoing

Dog, Chihuahua, Female, 1.5 year, 3.583 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 21 tablet per animal • Reactions: Leucocytosis NOS, Elevated bile acids, Overdose • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075415
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 1.50 Year
  • Weight: 3.583 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 21 tablet per animal
Reactions Reported:
Leucocytosis NOS Elevated bile acids Overdose
Outcomes: Ongoing

Dog, Terrier - Boston, Female, 2 year, 8.16 kilogram • Drug: MSK, Unknown • Reactions: Rash, Hair loss • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075064
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 2.00 Year
  • Weight: 8.160 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Rash Hair loss
Outcomes: Ongoing

Dog, Bulldog - English, Female, 11.2 year, 29.94 kilogram • Drug: MSK, Tablet, Oral • Reactions: Urinary incontinence • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075305
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.20 Year
  • Weight: 29.940 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Urinary incontinence
Outcomes: Ongoing

Dog, Shepherd Dog - German, Female, 10.9 year, 44.45 kilogram • Drug: MSK, Tablet, Oral • Reactions: Lack of efficacy - NOS, Seizure NOS, Other abnormal test result NOS, Unsteady walking (ataxia), Musculoskeletal disorder NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075291
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.90 Year
  • Weight: 44.450 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Lack of efficacy - NOS Seizure NOS Other abnormal test result NOS Unsteady walking (ataxia) Musculoskeletal disorder NOS Elevated serum alkaline phosphatase
Outcomes: Ongoing

Dog, Bulldog - English, Male, 8.58 year, 44.906 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy (protozoa) - Giardia, Lack of efficacy (endoparasite) - hookworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-074714
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 8.58 Year
  • Weight: 44.906 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy (protozoa) - Giardia Lack of efficacy (endoparasite) - hookworm
Outcomes: Outcome Unknown

Dog, ['Pointer (unspecified)', 'Dog (unknown)'], Male, 15 year, 35.698 kilogram • Drug: MSK, Tablet, Oral, Dose: 8 Milligram per animal • Reactions: Lack of efficacy - NOS, Death, Local erythema, Underdose, Tiredness (lethargy)… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-075270
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 35.698 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 8 Milligram per animal
Reactions Reported:
Lack of efficacy - NOS Death Local erythema Underdose Tiredness (lethargy) Blood in vomit
Outcomes: Died

Dog, Terrier - West Highland White, Female, 8 year, 6.53 kilogram • Drug: MSK, Tablet, Oral • Reactions: Partial lack of efficacy • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074452
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 6.530 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Partial lack of efficacy
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.